SS-31

The SS-31 peptide has a fascinating history, primarily in the field of mitochondrial medicine:

SS-31 was developed and designed to selectively bind to cardiolipin, a lipid unique to the inner mitochondrial membrane, stabilizing mitochondrial structure and function.

It targets the inner mitochondrial membrane, binding to cardiolipin, a phospholipid crucial for mitochondrial function. By doing so, SS-31 protects mitochondria from oxidative damage, reduces reactive oxygen species (ROS) production, and helps maintain mitochondrial integrity.

Potential Benefits & Mechanism of Action

• Mitochondrial Protection: SS-31 preserves mitochondrial function by reducing oxidative stress, which is crucial for cellular energy production and overall cell health.

• Anti-Aging Effects: Studies suggest that SS-31 may have anti-aging properties by preserving mitochondrial function and reducing age-related decline in tissues.

• Cardioprotective: SS-31 has shown promise in protecting the heart from ischemia-reperfusion injury, a common complication in cardiac surgeries and heart attacks.

• Neuroprotective: There's evidence indicating SS-31's potential in protecting neurons from damage, offering therapeutic potential for neurodegenerative diseases like Alzheimer's and Parkinson's.

• Anti-inflammatory: SS-31 exhibits anti-inflammatory properties, potentially beneficial in various inflammatory conditions.

Animal Studies: Several animal studies have demonstrated the efficacy of SS-31 in protecting tissues from damage in various models of disease and injury, including heart disease, neurodegeneration, and ischemia-reperfusion injury.

Human Trials: While there's ongoing research, human trials have shown promising results in certain conditions, such as heart failure and age-related macular degeneration, although larger studies are needed for definitive conclusions.Overall, SS-31's ability to target mitochondrial dysfunction and oxidative stress holds significant potential for various medical applications, from treating age-related conditions to protecting against tissue damage in acute injuries.

SS-31 binds to cardiolipin, stabilizing mitochondrial membranes and optimizing electron transport chain efficiency, leading to improved cellular bioenergetics.

Clinical trials have investigated SS-31 in conditions such as primary mitochondrial myopathy, heart failure, and age-related macular degeneration. Results have shown improvements in mitochondrial function and clinical symptoms, highlighting its therapeutic potential.